US20080081914A1 - Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof - Google Patents

Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof Download PDF

Info

Publication number
US20080081914A1
US20080081914A1 US11/867,219 US86721907A US2008081914A1 US 20080081914 A1 US20080081914 A1 US 20080081914A1 US 86721907 A US86721907 A US 86721907A US 2008081914 A1 US2008081914 A1 US 2008081914A1
Authority
US
United States
Prior art keywords
formula
benzo
isoxazol
preparation
methanesulfonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/867,219
Inventor
Gabriele Razzetti
Simone Mantegazza
Graziano Castaldi
Pietro Allegrini
Vittorio Lucchini
Alberto Bologna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dipharma SpA
Original Assignee
Dipharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20030026 external-priority patent/ITMI20030026A1/en
Priority claimed from IT001383A external-priority patent/ITMI20031383A1/en
Application filed by Dipharma SpA filed Critical Dipharma SpA
Priority to US11/867,219 priority Critical patent/US20080081914A1/en
Assigned to DIPHARMA S.P.A. reassignment DIPHARMA S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLEGRINI, PIETRO, BOLOGNA, ALBERTO, CASTALDI, GRAZIANO, LUCCHINI, VITTORIO, MANTEGAZZA, SIMONE, RAZZETTI, GABRIELE
Publication of US20080081914A1 publication Critical patent/US20080081914A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Definitions

  • the present invention relates to a process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid or a salt thereof, useful as an intermediate for the preparation of zonisamide, and intermediates thereof.
  • Zonisamide namely 3-(sulfamylmethyl)-benzo[d]isoxazole
  • Zonisamide is a known medicament having antiepileptic, anticonvulsive and antineurotoxic activities, belonging to the class of the sulfonamides, and having the following formula:
  • a process for the preparation of zonisamide comprises the sulfonation of 3-bromomethyl-benzo[d]isoxazole (1) with sodium sulfite to obtain benzo[d]isoxazol-3-yl-methanesulfonic acid sodium salt (2) which is then transformed into the corresponding sulfonyl chloride (3) by treatment with phosphorous oxychloride.
  • the reaction of the latter with gas ammonia yields zonisamide (4), as reported hereinbelow.
  • the starting compound (I) is not commercially available. Its preparation is described in BE 624463 ; Chem. Pharm. Bull. 24 (1976) p. 632; and Chim. Ter. 7 (1972) p. 127 starting from 4-hydroxycoumarin (5), according to the following scheme:
  • JP 53077057 discloses the preparation of intermediate (9), benzo[d]isoxazol-3-yl-methanesulfonic acid, by direct sulfonation of benzo[d]isoxazol-3-yl-acetic acid (6) with sulfonic chlorohydrin/dioxane.
  • JP 54163510 describes the synthesis of zonisamide (4) starting from 2-(2-hydroxy-phenyl)-2-oxo-ethanesulfonamide (10) by formation of the corresponding 2-hydroxyimmino-2-(2-hydroxy-phenyl)ethanesulfonamide (11) and subsequent thermal cyclization.
  • the present invention relates to a process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof,
  • Suitable benzo[d]isoxazol-3-yl-methanesulfonic acid salts of formula (I) are, for example, the alkali or alkaline-earth salts, in particular the sodium, potassium, lithium, calcium or barium, preferably sodium or lithium, salts; or the salts with organic bases, for example with a secondary or tertiary amine, typically triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]-undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, preferably triethylamine or 1,8-diazabicyclo[5,4,0]undec-4-ene.
  • the alkali or alkaline-earth salts in particular the sodium, potassium, lithium, calcium or barium
  • the invention also relates to both the benzo[d]isoxazol-3-yl-methanesulfonic acid lithium salt and the salts of benzo[d]isoxazol-3-yl-methanesulfonic acid with organic bases, for example with a secondary or tertiary amine, typically triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]-undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, preferably triethylamine or 1,8-diazabicyclo-[5,4,0]undec-4-ene, which are novel compounds.
  • a secondary or tertiary amine typically triethylamine, tributylamine, diisopropylethylamine,
  • the oxime of formula (III) spontaneously transforms into the corresponding benzo[d]isoxazol-3-yl-methanesulfonic acid salt of formula (I) by treatment with a basic agent.
  • the basic agent is preferably a hydroxide of an alkali or alkaline-earth metal, for example lithium, sodium, potassium, calcium or magnesium, in particular lithium or sodium, or an organic base, for example a secondary or tertiary amine, typically triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo-[5,4,0]undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, preferably triethylamine or 1,8-diazabicyclo[5,4,0]undec-4-ene.
  • the basic agent can be used in a reaction ratio from approx. one to two equivalents with respect to the amount of oxime, preferably in a stoichiometric amount.
  • the transformation reaction can be carried out, depending on the base, in the absence or in the presence of a solvent selected, for example, from the group consisting of water; ethers, in particular tetrahydrofuran; C 1 -C 4 alkanols, particularly methanol or ethanol; acetonitrile; chlorinated solvents, such as dichloromethane, dichloroethane or trichloroethane; carboxylic acids alkyl esters, such as ethyl acetate; apolar aprotic solvents, such as toluene or cyclohexane; or mixtures thereof, such as tetrahydrofuran/water, acetonitrile/water, ethyl acetate/methanol or acetonitrile/methanol.
  • a solvent selected, for example, from the group consisting of water; ethers, in particular tetrahydrofuran; C 1 -C 4 alkanols, particularly methanol
  • the reaction is preferably carried out in water, acetonitrile/methanol or dichloromethane.
  • the reaction is preferably carried out at a temperature ranging from about ⁇ 20° C. to the reflux temperature of the solvent or solvent mixture, in particular at temperatures approx. ranging from 30 to 50° C.
  • the resulting salt of a compound of formula (I) can be recovered directly or, if desired, can be converted into the free acid with known methods.
  • the process of the invention allows to obtain benzo[d]isoxazol-3-yl-methanesulfonic salt, or a salt thereof, with less environmental impact, in purer form and higher yields than with the method disclosed in U.S. Pat. No. 4,172,896.
  • oxime of formula (III) is treated with lithium or sodium hydroxide, triethylamine or diazabicycloundecene.
  • Treatment with these specific basic agents allows, in fact, to obtain benzo[d]isoxazol-3-yl-methanesulfonic acid in purer form and higher yields than when using other basic agents.
  • the reaction is carried out in water, in an organic solvent or in mixtures thereof.
  • the organic solvent can be an organic protic solvent, such as a C 1 -C 6 alkanol, in particular methanol, ethanol or isopropanol; a halo hydrocarbon, such as chloroform or dichloromethane; an aromatic hydrocarbon, such as benzene or toluene; an ether, such as diethyl ether or tetrahydrofuran; or a carboxylic acid alkyl ester, such as ethyl acetate.
  • organic protic solvent such as a C 1 -C 6 alkanol, in particular methanol, ethanol or isopropanol
  • a halo hydrocarbon such as chloroform or dichloromethane
  • an aromatic hydrocarbon such as benzene or toluene
  • an ether such as diethyl ether or tetrahydrofuran
  • carboxylic acid alkyl ester such
  • Hydroxylamine can be used as an aqueous solution, or can be obtained in situ in the reaction medium from a salt thereof, for example sulfate, nitrate or chloride, by reaction with a suitable basic agent, such as sodium hydroxide, sodium carbonate or organic bases, such as triethylamine.
  • a suitable basic agent such as sodium hydroxide, sodium carbonate or organic bases, such as triethylamine.
  • the resulting oxime of formula (III) can be crystallized for instance from C 1 -C 4 alkanols in particular isopropanol, C 1 -C 4 alkanols aqueous mixtures in particular isopropanol/water, toluene or dichloromethane/water mixtures.
  • a crystalline oxime of formula (III), and the isomers thereof, in particular having the tabulation of peak position from X-Ray Powder pattern listed in Table 1, is novel and is a further object of the invention.
  • TABLE 1 X-Ray Powder Diffraction Significant Peaks I/Imax Nr. 2-Theta (degrees) ⁇ 0.1 d( ⁇ ) (%) 1 8.5 10.37 21 2 11.2 7.87 6 3 16.4 5.40 17 4 17.2 5.15 100 5 20.1 4.41 7 6 22.5 3.94 12 7 23.7 3.74 7 8 24.3 3.65 5 9 26.0 3.42 5 10 28.6 3.11 25
  • Ketosultone of formula (II) is known and can be obtained in small amounts with known, rather inexpensive methods, for example according to Int. J. Sulfur. Chem ., Part A, (1992), 2(4), 249-255; or Arch. Pharm, 313, 1980. p. 249.
  • the synthetic route therein described is the following:
  • the process comprises the mesylation of salicylaldehyde (12) and the subsequent cyclization of derivative (13) with potassium hydroxide.
  • the resulting compound (14) is oxidized to the desired compound (II) by use of potassium dichromate and sulfuric acid. This procedure cannot however be adopted to obtain ketosultone (II) in industrial amounts, in that it involves the use of potassium dichromate, which is known to be carcinogenic, teratogenic and highly toxic to the environment.
  • ketosultone of formula (II) i.e. 2,2-dioxo-2,3-dihydro-2lambda*6*-benzo[e][1,2]oxathiin-4-one, can be conveniently prepared on an industrial scale by means of a process comprising the reaction of a compound of formula (V)
  • a suitable basic agent is typically an agent selected from the group consisting of an alkali or alkaline-earth metal C 1 -C 8 alkoxide, or a tertiary amine or catalytic amounts thereof.
  • An alkali or alkaline-earth metal C 1 -C 8 alkoxide can be a sodium or potassium salt with a straight or branched C 1 -C 5 alkanol, typically methanol, ethanol, tert-butanol and isoamyl alcohol, preferably sodium tert-butylate.
  • the tertiary amine is an amine having such basicity as to induce the conversion of a compound of formula (V) into a ketosultone of formula (II).
  • tertiary amines are 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, in particular 1,8-diazabicyclo[5,4,0]undec-4-ene.
  • the molar ratio of tertiary amine to compound of formula (V) can for instance range from about 10/1 to 2/1, preferably approximately from 2.2/1 to 2.1/1.
  • the reaction between a compound of formula (V) and a basic agent is preferably carried out in an organic solvent selected, for example, from a chlorinated solvent such as C 1 -C 4 alkyl hydrocarbons mono-, di-, tri- and tetra-chlorides, typically dichloromethane, trichloromethane, tetrachloromethane, trichloroethane or tetrachloroethane, in particular dichloroethane; an ether, such as diethyl ether or tetrahydrofuran, preferably tetrahydrofuran; an apolar aprotic solvent, such as pentane, hexane, cyclohexane, benzene, toluene, preferably toluene; a dipolar aprotic solvent, for example dimethylformamide or N-methylpyrrolidone; and acetonitrile. More preferably the solvent is tetrahydrofuran
  • ketosultone of formula (II) can be obtained by reacting a compound of formula (V) in an organic solvent, as exemplified above, with catalytic amounts of said tertiary amine, for example about 10-20% molar, in the presence of carbonates or hydroxides of alkali or alkaline-earth metals such as lithium, sodium, potassium, calcium, magnesium; preferably potassium carbonate.
  • a compound of formula (V) can be prepared by acylation of a compound of formula (VI)
  • acylating agent of formula CH 3 SO 2 X wherein X is halogen, such as chlorine or bromine, preferably chlorine.
  • X is halogen, such as chlorine or bromine, preferably chlorine.
  • Acylation of a compound of formula (VI) can be carried out with known methods, for example as illustrated in the following experimental section, in particular in an apolar aprotic solvent as exemplified above.
  • ketosultone of formula (II) in yields ranging from 50 to 80%, using intermediates which do not involve hazards to the handler or the environment, while being well-suited to the industrial production. Finally, ketosultone (II) can be easily isolated following work-up with acids.
  • Ketosultone of formula (II), used in the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I) or a salt thereof, is preferably prepared according to the process of the invention.
  • a further object of the invention is therefore a process for the preparation of zonisamide, comprising the treatment of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof, with an halogenating agent to obtain a benzo[d]isoxazol-3-yl-methanesulfonyl halide of formula (IV) wherein X is halogen, preferably chlorine or bromine, and following treatment of (IV) with ammonia; wherein the benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof, is obtained by a process comprising the treatment of an oxime of formula (III) with a basic agent as defined above
  • the basic agent is preferably lithium or sodium hydroxide, triethylamine or diazabicycloundecene.
  • a suitable halogenating agent is for example phosphorous oxychloride or phosphorous oxybromide.
  • an oxime of formula (III) and the isomers thereof if the case in crystalline form,
  • ketosultone (II) (50.0 g; 252.5 mmol) in 150 ml of methanol is added at room temperature with hydroxylamine hydrochloride (18.0 g; 252.5 mmol). The suspension is added dropwise with triethylamine (25.5 g; 252.5 mmol) in about 1 hour. The resulting solution is stirred for 1-2 hours, then diluted with 300 ml of water. The corresponding oxime (III) precipitates, which is filtered and washed with water. (50.3 g; yield: 95%).
  • ketosultone (II) (50.0 g; 252.5 mmol) in 500 ml of dichloromethane is added at room temperature with hydroxylamine hydrochloride (18.0 g; 252.5 mmol). The suspension is added dropwise with triethylamine (25.5 g; 252.5 mmol) in about 1 hour. The resulting solution is stirred for 1-2 hours, then washed with 300 ml of water. The solvent is evaporated off and the residue is re-crystallized from toluene (650 ml), thereby obtaining a corresponding crystalline oxime (III) (40.2 g; yield: 76%). Relevant X-Ray Powder pattern is shown in Table 1 above.
  • a solution of a mesylate (V) (5.0 g; 17.1 mmol) in 20 ml of tetrahydrofuran is added with 5.5 g (35.9 mmol) of 1,8-diazabicyclo[5,4,0]undec-4-ene.
  • the reaction mixture is stirred for about 12 hours at room temperature (approx. 20-25° C.).
  • the solution is then heated to 35° C. for about 2 hours, then diluted with 20 ml of water.
  • Tetrahydrofuran is then distilled off under vacuum. Upon acidification of residue to pH ⁇ 3, the product starts to crystallize.
  • the mixture is cooled to about 0-5° C.

Abstract

A process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I),
Figure US20080081914A1-20080403-C00001
or a salt thereof, and the intermediates thereof, useful as an intermediate in the preparation of zonisamide.

Description

  • The present invention relates to a process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid or a salt thereof, useful as an intermediate for the preparation of zonisamide, and intermediates thereof.
  • TECHNOLOGICAL BACKGROUND
  • Zonisamide, namely 3-(sulfamylmethyl)-benzo[d]isoxazole, is a known medicament having antiepileptic, anticonvulsive and antineurotoxic activities, belonging to the class of the sulfonamides, and having the following formula:
    Figure US20080081914A1-20080403-C00002
  • A process for the preparation of zonisamide, disclosed in U.S. Pat. No. 4,172,896, comprises the sulfonation of 3-bromomethyl-benzo[d]isoxazole (1) with sodium sulfite to obtain benzo[d]isoxazol-3-yl-methanesulfonic acid sodium salt (2) which is then transformed into the corresponding sulfonyl chloride (3) by treatment with phosphorous oxychloride. The reaction of the latter with gas ammonia yields zonisamide (4), as reported hereinbelow.
    Figure US20080081914A1-20080403-C00003
  • The starting compound (I) is not commercially available. Its preparation is described in BE 624463; Chem. Pharm. Bull. 24 (1976) p. 632; and Chim. Ter. 7 (1972) p. 127 starting from 4-hydroxycoumarin (5), according to the following scheme:
    Figure US20080081914A1-20080403-C00004
  • Hydroxycoumarin (5) is treated with hydroxylamine to obtain benzo[d]isoxazol-3-yl-acetic acid (6) which is brominated at the alpha position to give benzo[d]isoxazol-3-yl-bromoacetic acid (7) from which 3-bromomethyl-benzo[d]isoxazole (8) is obtained by decarboxylation. The development of this process is limited in that the starting intermediate (I) is not commercially available and therefore the preparation of zonisamide is very complex. In fact, Posner reaction for the preparation of acid (6) requires the use of metal sodium. Moreover, when metal sodium is used in alcoholic solution, besides acid (6) also remarkable amounts of O-hydroxy-acetophenone-oxime as by-product are obtained. Furthermore, the decarboxylation reaction to give compound (8) requires drastic conditions, namely the presence of a large excess of 50% sulfuric acid and reflux temperature, and the resulting product is thus difficult to be isolated.
  • A number of alternative processes for the preparation of zonisamide are known. By way of example, JP 53077057 discloses the preparation of intermediate (9), benzo[d]isoxazol-3-yl-methanesulfonic acid, by direct sulfonation of benzo[d]isoxazol-3-yl-acetic acid (6) with sulfonic chlorohydrin/dioxane.
    Figure US20080081914A1-20080403-C00005
  • The use of sulfonic chlorohydrin and dioxane is disadvantageous, as these products are highly toxic and difficult to handle.
  • JP 54163510 describes the synthesis of zonisamide (4) starting from 2-(2-hydroxy-phenyl)-2-oxo-ethanesulfonamide (10) by formation of the corresponding 2-hydroxyimmino-2-(2-hydroxy-phenyl)ethanesulfonamide (11) and subsequent thermal cyclization.
    Figure US20080081914A1-20080403-C00006
  • The main drawbacks of this synthetic route are that the starting product (10) is not commercially available and the yield is low (approx. 6%, calculated on the last step). There is therefore the need for an alternative method which allows to prepare zonisamide in highly pure form and good yield, suitable for the preparation on an industrial scale.
  • DETAILED DISCLOSURE OF THE INVENTION
  • The present invention relates to a process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof,
    Figure US20080081914A1-20080403-C00007
  • comprising the reaction of an oxime of formula (III)
    Figure US20080081914A1-20080403-C00008
  • with a basic agent.
  • Suitable benzo[d]isoxazol-3-yl-methanesulfonic acid salts of formula (I) are, for example, the alkali or alkaline-earth salts, in particular the sodium, potassium, lithium, calcium or barium, preferably sodium or lithium, salts; or the salts with organic bases, for example with a secondary or tertiary amine, typically triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]-undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, preferably triethylamine or 1,8-diazabicyclo[5,4,0]undec-4-ene.
  • The invention also relates to both the benzo[d]isoxazol-3-yl-methanesulfonic acid lithium salt and the salts of benzo[d]isoxazol-3-yl-methanesulfonic acid with organic bases, for example with a secondary or tertiary amine, typically triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]-undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, preferably triethylamine or 1,8-diazabicyclo-[5,4,0]undec-4-ene, which are novel compounds.
  • The oxime of formula (III) spontaneously transforms into the corresponding benzo[d]isoxazol-3-yl-methanesulfonic acid salt of formula (I) by treatment with a basic agent. The basic agent is preferably a hydroxide of an alkali or alkaline-earth metal, for example lithium, sodium, potassium, calcium or magnesium, in particular lithium or sodium, or an organic base, for example a secondary or tertiary amine, typically triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo-[5,4,0]undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, preferably triethylamine or 1,8-diazabicyclo[5,4,0]undec-4-ene.
  • The basic agent can be used in a reaction ratio from approx. one to two equivalents with respect to the amount of oxime, preferably in a stoichiometric amount.
  • The transformation reaction can be carried out, depending on the base, in the absence or in the presence of a solvent selected, for example, from the group consisting of water; ethers, in particular tetrahydrofuran; C1-C4 alkanols, particularly methanol or ethanol; acetonitrile; chlorinated solvents, such as dichloromethane, dichloroethane or trichloroethane; carboxylic acids alkyl esters, such as ethyl acetate; apolar aprotic solvents, such as toluene or cyclohexane; or mixtures thereof, such as tetrahydrofuran/water, acetonitrile/water, ethyl acetate/methanol or acetonitrile/methanol. The reaction is preferably carried out in water, acetonitrile/methanol or dichloromethane. The reaction is preferably carried out at a temperature ranging from about −20° C. to the reflux temperature of the solvent or solvent mixture, in particular at temperatures approx. ranging from 30 to 50° C. The resulting salt of a compound of formula (I) can be recovered directly or, if desired, can be converted into the free acid with known methods. The process of the invention allows to obtain benzo[d]isoxazol-3-yl-methanesulfonic salt, or a salt thereof, with less environmental impact, in purer form and higher yields than with the method disclosed in U.S. Pat. No. 4,172,896. This particularly applies when oxime of formula (III) is treated with lithium or sodium hydroxide, triethylamine or diazabicycloundecene. Treatment with these specific basic agents allows, in fact, to obtain benzo[d]isoxazol-3-yl-methanesulfonic acid in purer form and higher yields than when using other basic agents.
  • An oxime of formula (III) and the isomers thereof can be obtained by reaction of a ketosultone of formula (II)
    Figure US20080081914A1-20080403-C00009
  • with hydroxylamine, at a temperature ranging from about 5 to about 100° C., preferably at temperatures ranging from about 15 to about 40° C. The reaction is carried out in water, in an organic solvent or in mixtures thereof. The organic solvent can be an organic protic solvent, such as a C1-C6 alkanol, in particular methanol, ethanol or isopropanol; a halo hydrocarbon, such as chloroform or dichloromethane; an aromatic hydrocarbon, such as benzene or toluene; an ether, such as diethyl ether or tetrahydrofuran; or a carboxylic acid alkyl ester, such as ethyl acetate.
  • Hydroxylamine can be used as an aqueous solution, or can be obtained in situ in the reaction medium from a salt thereof, for example sulfate, nitrate or chloride, by reaction with a suitable basic agent, such as sodium hydroxide, sodium carbonate or organic bases, such as triethylamine. The resulting oxime of formula (III), if desired, can be crystallized for instance from C1-C4 alkanols in particular isopropanol, C1-C4 alkanols aqueous mixtures in particular isopropanol/water, toluene or dichloromethane/water mixtures. A crystalline oxime of formula (III), and the isomers thereof, in particular having the tabulation of peak position from X-Ray Powder pattern listed in Table 1, is novel and is a further object of the invention.
    TABLE 1
    X-Ray Powder Diffraction Significant Peaks
    I/Imax
    Nr. 2-Theta (degrees) ± 0.1 d(Å) (%)
    1 8.5 10.37 21
    2 11.2 7.87 6
    3 16.4 5.40 17
    4 17.2 5.15 100
    5 20.1 4.41 7
    6 22.5 3.94 12
    7 23.7 3.74 7
    8 24.3 3.65 5
    9 26.0 3.42 5
    10 28.6 3.11 25
  • Ketosultone of formula (II) is known and can be obtained in small amounts with known, rather inexpensive methods, for example according to Int. J. Sulfur. Chem., Part A, (1992), 2(4), 249-255; or Arch. Pharm, 313, 1980. p. 249. The synthetic route therein described is the following:
    Figure US20080081914A1-20080403-C00010
  • The process comprises the mesylation of salicylaldehyde (12) and the subsequent cyclization of derivative (13) with potassium hydroxide. The resulting compound (14) is oxidized to the desired compound (II) by use of potassium dichromate and sulfuric acid. This procedure cannot however be adopted to obtain ketosultone (II) in industrial amounts, in that it involves the use of potassium dichromate, which is known to be carcinogenic, teratogenic and highly toxic to the environment.
  • Another synthetic route is known from Heterocycles, vol. 22, n° 10, 1984, p. 2293, in which
    Figure US20080081914A1-20080403-C00011

    the ring closure is obtained by treatment of methyl salicylate mesylate (16) with sodium hydride in dimethylformamide (DMF). On the other hand, it is known from literature (e.g. Bretherick's Handbook of reactive chemical hazards, VI Ed., p 1181) that the sodium hydride-DMF mixture is potentially hazardous and easily undergoes uncontrollable, explosive reactions, even at room temperature. Therefore, this procedure can not be used on an industrial scale.
  • It has now been found that ketosultone of formula (II), i.e. 2,2-dioxo-2,3-dihydro-2lambda*6*-benzo[e][1,2]oxathiin-4-one, can be conveniently prepared on an industrial scale by means of a process comprising the reaction of a compound of formula (V)
    Figure US20080081914A1-20080403-C00012
  • with a basic agent.
  • A suitable basic agent is typically an agent selected from the group consisting of an alkali or alkaline-earth metal C1-C8 alkoxide, or a tertiary amine or catalytic amounts thereof.
  • An alkali or alkaline-earth metal C1-C8 alkoxide can be a sodium or potassium salt with a straight or branched C1-C5 alkanol, typically methanol, ethanol, tert-butanol and isoamyl alcohol, preferably sodium tert-butylate.
  • The tertiary amine is an amine having such basicity as to induce the conversion of a compound of formula (V) into a ketosultone of formula (II). Examples of such tertiary amines are 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]undec-4-ene or 1,5-diazabicyclo[4,3,0]non-5-ene, in particular 1,8-diazabicyclo[5,4,0]undec-4-ene. The molar ratio of tertiary amine to compound of formula (V) can for instance range from about 10/1 to 2/1, preferably approximately from 2.2/1 to 2.1/1.
  • The reaction between a compound of formula (V) and a basic agent is preferably carried out in an organic solvent selected, for example, from a chlorinated solvent such as C1-C4 alkyl hydrocarbons mono-, di-, tri- and tetra-chlorides, typically dichloromethane, trichloromethane, tetrachloromethane, trichloroethane or tetrachloroethane, in particular dichloroethane; an ether, such as diethyl ether or tetrahydrofuran, preferably tetrahydrofuran; an apolar aprotic solvent, such as pentane, hexane, cyclohexane, benzene, toluene, preferably toluene; a dipolar aprotic solvent, for example dimethylformamide or N-methylpyrrolidone; and acetonitrile. More preferably the solvent is tetrahydrofuran.
  • Alternatively, the conversion into ketosultone of formula (II) can be obtained by reacting a compound of formula (V) in an organic solvent, as exemplified above, with catalytic amounts of said tertiary amine, for example about 10-20% molar, in the presence of carbonates or hydroxides of alkali or alkaline-earth metals such as lithium, sodium, potassium, calcium, magnesium; preferably potassium carbonate.
  • The reaction is carried out at a temperature ranging from 0° C. to the reflux temperature of the reaction mixture, preferably from room temperature to 40° C., for times from an hour to 18 hours, depending on the basic agent. A compound of formula (V) can be prepared by acylation of a compound of formula (VI)
    Figure US20080081914A1-20080403-C00013
  • with an acylating agent of formula CH3SO2X, wherein X is halogen, such as chlorine or bromine, preferably chlorine. Acylation of a compound of formula (VI) can be carried out with known methods, for example as illustrated in the following experimental section, in particular in an apolar aprotic solvent as exemplified above.
  • This process, which is a further object of the invention, allows to prepare ketosultone of formula (II) in yields ranging from 50 to 80%, using intermediates which do not involve hazards to the handler or the environment, while being well-suited to the industrial production. Finally, ketosultone (II) can be easily isolated following work-up with acids.
  • Ketosultone of formula (II), used in the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I) or a salt thereof, is preferably prepared according to the process of the invention.
  • The processes of the invention for the preparation of both benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof, and the intermediates of formula (II) and (III), allow to obtain zonisamide at lower costs and higher purity degree than the process disclosed in U.S. Pat. No. 4,172,896.
  • A further object of the invention is therefore a process for the preparation of zonisamide, comprising the treatment of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof,
    Figure US20080081914A1-20080403-C00014

    with an halogenating agent to obtain a benzo[d]isoxazol-3-yl-methanesulfonyl halide of formula (IV)
    Figure US20080081914A1-20080403-C00015

    wherein X is halogen, preferably chlorine or bromine, and following treatment of (IV) with ammonia; wherein the benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof, is obtained by a process comprising the treatment of an oxime of formula (III) with a basic agent as defined above
    Figure US20080081914A1-20080403-C00016
  • The basic agent is preferably lithium or sodium hydroxide, triethylamine or diazabicycloundecene. A suitable halogenating agent is for example phosphorous oxychloride or phosphorous oxybromide.
  • The steps for the conversion of a compound of formula (I), or a salt thereof, into a compound of formula (IV) and then into zonisamide can be carried out as disclosed in U.S. Pat. No. 4,172,896.
  • According to a preferred aspect of the invention, an oxime of formula (III) and the isomers thereof, if the case in crystalline form,
    Figure US20080081914A1-20080403-C00017
  • is prepared by a process comprising:
      • the reaction of a compound of formula (V)
        Figure US20080081914A1-20080403-C00018
  • with a basic agent, as defined above, to obtain a ketosultone of formula (II),
    Figure US20080081914A1-20080403-C00019

    the reaction of compound (II) with hydroxylamine, and, if desired, subsequent crystallization of the product thus obtained.
  • The following examples further illustrate the invention.
  • EXAMPLE 1 Preparation of the Oxime of Formula (III)
  • A solution of ketosultone (II) (50.0 g; 252.5 mmol) in 150 ml of methanol is added at room temperature with hydroxylamine hydrochloride (18.0 g; 252.5 mmol). The suspension is added dropwise with triethylamine (25.5 g; 252.5 mmol) in about 1 hour. The resulting solution is stirred for 1-2 hours, then diluted with 300 ml of water. The corresponding oxime (III) precipitates, which is filtered and washed with water. (50.3 g; yield: 95%).
  • EXAMPLE 2 Preparation of the Oxime of Formula (III) in Crystalline Form
  • A solution of ketosultone (II) (50.0 g; 252.5 mmol) in 500 ml of dichloromethane is added at room temperature with hydroxylamine hydrochloride (18.0 g; 252.5 mmol). The suspension is added dropwise with triethylamine (25.5 g; 252.5 mmol) in about 1 hour. The resulting solution is stirred for 1-2 hours, then washed with 300 ml of water. The solvent is evaporated off and the residue is re-crystallized from toluene (650 ml), thereby obtaining a corresponding crystalline oxime (III) (40.2 g; yield: 76%). Relevant X-Ray Powder pattern is shown in Table 1 above.
  • 1H-NMR-300 Mhz-(DMSO-d6): δ 5.06 (s, 2H); 7.33 (m, 2H); 7.55 (dd, 1H); 8.0 (d, 1H).
  • Mass spectrum: E.I.-m/e: M+213
  • EXAMPLE 3 Preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid lithium salt (I)
  • A suspension of oxime (III) (50 g; 265.7 mmol) in 250 ml of water is added dropwise with a 2 M lithium hydroxide solution (134 ml; 265.7 mmols) in water. After reacting for 3 hours at room temperature, the solution is evaporated to residue, then added with toluene and residual humidity is azeotropically removed. The product is then filtered and dried under vacuum, thereby obtaining 48 g of benzo[d]isoxazol-3-yl-methanesulfonic acid lithium salt (Yield: 85%).
  • EXAMPLE 4 Preparation of the benzo[d]isoxazol-3-yl-methanesulfonic acid, sodium salt (I)
  • A suspension of oxime (III) (50 g; 265.7 mmol) in 250 ml of water is added dropwise with a 2 M sodium hydroxide solution (134 ml; 265.7 mmol) in water. After reacting for 3 hours at room temperature the solution is evaporated to residue, then added with toluene and residual humidity is azeotropically removed. The product is then filtered and dried under vacuum, thereby obtaining 43 g of benzo[d]isoxazol-3-yl-methanesulfonic acid sodium salt. (Yield: 70%).
  • EXAMPLE 5 Preparation of 2,2-dioxo-2,3-dihydro-2lambda*6*-benzo[e][1,2]oxathiin-4-one; Ketosultone of Formula (II)
  • A solution of a mesylate (V) (5.0 g; 17.1 mmol) in 20 ml of tetrahydrofuran is added with 5.5 g (35.9 mmol) of 1,8-diazabicyclo[5,4,0]undec-4-ene. The reaction mixture is stirred for about 12 hours at room temperature (approx. 20-25° C.). The solution is then heated to 35° C. for about 2 hours, then diluted with 20 ml of water. Tetrahydrofuran is then distilled off under vacuum. Upon acidification of residue to pH<3, the product starts to crystallize. The mixture is cooled to about 0-5° C. and the product is filtered, washed with water and dried under vacuum, thereby obtaining 2.8 g of ketosultone (II) (Yield: 80%) 1H NMR: (CDCl3): δ ppm: 4.4 ppm (s, 2H); 7.3 ppm (d, 1H); 7.4 ppm (t, 1H); 7.7 (t, 1H); 8.1 (d, 1H).
  • EXAMPLE 6 Preparation of 2,2-dioxo-2,3-dihydro-2lambda*6*-benzo[e][1,2]oxathiin-4-one; Ketosultone of Formula (II)
  • A solution of a mesylate (V) (5.0 g; 17.1 mmol) in 20 ml of tetrahydrofuran is added with 0.5 g (3.59 mmol) of 1,8-diazabicyclo[5,4,0]undec-4-ene, 5.0 g (36.2 mmol) of potassium carbonate and 5.0 g of water. The mixture is stirred to about 30-35° C. for 10-14 hours, after that it is diluted with 20 ml of water and THF is distilled off under vacuum. Upon acidification of residue to pH<3, the product starts to crystallize. The mixture is cooled to about 0-5° C. and the product is filtered, washed with water and dried under vacuum, thereby obtaining 2.2 g of ketosultone (II). (Yield: 65%).
  • EXAMPLE 7 Preparation of Mesylate of Formula (V)
  • 100 g (467 mmol) of phenyl salicylate (VI) and 54.5 g (476 mmol) of methanesulfonyl chloride are reacted in 500 ml of toluene, under stirring. The solution is cooled to about 0-5° C. and 48.7 g (481 mmol) of triethylamine are dropped therein in about 15 minutes. The reaction temperature raises to about 37° C. Afterwards the mixture is stirred at about 20-25° C. for 10-14 hours, monitoring the reaction by NMR and/or HPLC. Finally the solution is diluted with 500 ml of water. The formed precipitate is filtered. The organic filtrate is separated and evaporated under vacuum. The residue is combined with the precipitate and dried under vacuum at 60° C. for about 3 hours, thereby obtaining 130 g of product.
  • 1H NMR: (CDCl3): δ ppm: 3.3 ppm (s, 3H); 7.2 ppm (m, 3H); 7.4 ppm (m, 4H); 7.6 (t, 1H); 8.2 (d, 1H).
  • EXAMPLE 8 Preparation of the benzo[d]isoxazol-3-yl-methanesulfonic acid triethylammonium salt (I)
  • A solution of oxime (III) (50 g; 265.7 mmol) in 25 ml of methanol is added dropwise drop with triethylamine (26.7 g; 265.7 mmol) in water. After reacting for 8 hours at about 40° C., the solution is evaporated to a residue, thereby obtaining 57 g of benzo[d]isoxazol-3-yl-methanesulfonic acid triethylammonium salt (Yield: 70%).
  • EXAMPLE 9 Preparation of 2,2-dioxo-2,3-dihydro-2lambda*6*-benzo[e][1,2]oxathiin-4-one; Ketosultone of Formula (II)
  • A solution of a mesylate (V) (5.0 g; 17.1 mmol) in 20 ml of tetrahydrofuran is added with 3.45 g (35.9 mmol) of sodium tert-butoxide. The reaction mixture is stirred for about 12 hours at room temperature (approx. 20-25° C.). The solution is then heated to about 35° C. for approx. 2 hours, then diluted with 20 ml of water. Tetrahydrofuran is then distilled off under vacuum. Upon acidification of residue to pH<3, the product starts to crystallize. The mixture is cooled to about 0-5° C. and the product is filtered, washed with water and dried under vacuum, thereby obtaining 2.4 g of ketosultone (II) (Yield: 70%).

Claims (2)

1. A benzo[d]isoxazol-3-yl-methanesulfonic acid salt, which is the lithium salt or the salt with an organic base.
2. The salt as claimed in claim 1, wherein the organic base is a secondary or tertiary amine.
US11/867,219 2003-01-10 2007-10-04 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof Abandoned US20080081914A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/867,219 US20080081914A1 (en) 2003-01-10 2007-10-04 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ITMI2003A000026 2003-01-10
ITMI20030026 ITMI20030026A1 (en) 2003-01-10 2003-01-10 PROCEDURE FOR THE PREPARATION OF BENZOIC ACID
IT001383A ITMI20031383A1 (en) 2003-07-04 2003-07-04 PROCEDURE FOR THE PREPARATION OF BENZO (D) ISOSSAZOL-3-IL-METANSOLPHONIC ACID AND ITS INTERMEDIATES.
ITMI2003A001383 2003-07-04
US10/541,607 US7291742B2 (en) 2003-01-10 2003-12-24 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
PCT/EP2003/014919 WO2004063173A1 (en) 2003-01-10 2003-12-24 A process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
US11/867,219 US20080081914A1 (en) 2003-01-10 2007-10-04 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/014919 Division WO2004063173A1 (en) 2003-01-10 2003-12-24 A process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
US10/541,607 Division US7291742B2 (en) 2003-01-10 2003-12-24 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof

Publications (1)

Publication Number Publication Date
US20080081914A1 true US20080081914A1 (en) 2008-04-03

Family

ID=32715261

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/541,607 Expired - Fee Related US7291742B2 (en) 2003-01-10 2003-12-24 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
US11/867,219 Abandoned US20080081914A1 (en) 2003-01-10 2007-10-04 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/541,607 Expired - Fee Related US7291742B2 (en) 2003-01-10 2003-12-24 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof

Country Status (7)

Country Link
US (2) US7291742B2 (en)
EP (1) EP1581508A1 (en)
JP (1) JP2006515322A (en)
AU (1) AU2003298248A1 (en)
CA (1) CA2512791A1 (en)
PL (1) PL376216A1 (en)
WO (1) WO2004063173A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745471B2 (en) * 2004-06-18 2010-06-29 Chemagis Ltd. Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide
WO2014068460A2 (en) * 2012-11-02 2014-05-08 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases and neurological disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US6677458B2 (en) * 2001-03-02 2004-01-13 Teva Pharmaceutical Industries Ltd. Process for the preparation of 1,2-benzisoxazole-3-acetic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033114B2 (en) * 1976-12-16 1985-08-01 大日本製薬株式会社 1,2-benzisoxazole derivative
JPS5826857B2 (en) * 1977-12-02 1983-06-06 株式会社東芝 Driving method of variable frequency divider circuit
JPS54163823A (en) * 1978-06-12 1979-12-26 Dainippon Pharmaceutical Co Antiiepileptic agent based on 33sulphamoylmethyll 1*22benzisoxazole
EP1430037A4 (en) * 2001-08-30 2004-11-17 Teva Pharma Zonisamide intermediate and synthesis
AP2004003049A0 (en) * 2001-11-08 2004-06-30 Elan Pharm Inc N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives.
AU2003219889A1 (en) * 2002-02-22 2003-09-09 Teva Pharmaceutical Industries Ltd. Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US6677458B2 (en) * 2001-03-02 2004-01-13 Teva Pharmaceutical Industries Ltd. Process for the preparation of 1,2-benzisoxazole-3-acetic acid

Also Published As

Publication number Publication date
CA2512791A1 (en) 2004-07-29
WO2004063173A1 (en) 2004-07-29
EP1581508A1 (en) 2005-10-05
US7291742B2 (en) 2007-11-06
US20060135582A1 (en) 2006-06-22
PL376216A1 (en) 2005-12-27
JP2006515322A (en) 2006-05-25
AU2003298248A1 (en) 2004-08-10

Similar Documents

Publication Publication Date Title
US8884016B2 (en) Apixaban preparation process
EP1767538B1 (en) Process for producing 1-oxacephalosporin-7alpha-methoxy-3-chloromethyl derivative
US9000195B2 (en) Process for obtaining olopatadine and intermediates
US10358423B2 (en) Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamdes
ES2361330T3 (en) PROCEDURE FOR THE PREPARATION OF TOLTERODINE.
TWI695824B (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
CN114144406A (en) Method for producing methylene disulfonate compound
EP2024369A2 (en) Novel process for the preparation of sildenafil citrate
US20080081914A1 (en) Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
KR101100064B1 (en) Process for preparing nitrooxyderivatives of naproxen
JP3433319B2 (en) Method for producing o- (carboalkoxy) phenylmethanesulfonyl derivative
ES2224199T3 (en) PROCEDURE FOR OBTAINING 3- (HIDROXIFENIL -1- ALCOXIIMINOMETIL) DIOXAZINES.
EP1812395B1 (en) Method for the preparation of aripiprazole, and corresponding intermediates and their preparation
US20060142595A1 (en) Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI
WO2005030738A1 (en) Improved process for the preparation of intermediates useful for the preparation of zonisamide
US8563766B2 (en) Indane derivatives for use as intermediates
CN114144407B (en) Process for producing cyclic disulfonate compound
KR100339831B1 (en) New ethyl arizidine derivatives and their preparation methods
CN114716428B (en) Method for preparing metazopyr intermediate
JP4600859B2 (en) Heterocyclic substituted thiophenol compounds, intermediates for production thereof, and production methods
US10647667B2 (en) Method for preparing 3-substituted 2-vinylphenyl sulfonates
US5210218A (en) 2- and 3-chloropyrroles and process for preparing the same
TW201938529A (en) Method for manufacturing mercaptophenol compound and intermediate thereof
JP3283959B2 (en) D-biotin intermediate and method for producing the same
KR101095706B1 (en) A novel process for preparing montelukast or its sodium salt

Legal Events

Date Code Title Description
AS Assignment

Owner name: DIPHARMA S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAZZETTI, GABRIELE;MANTEGAZZA, SIMONE;CASTALDI, GRAZIANO;AND OTHERS;REEL/FRAME:019921/0433

Effective date: 20050523

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION